We have three newly approved meds for dementia. Brexpiprazole (Rexulti) for agitation, and donanemab (Kisunla) and lecanemab (Leqembi) for the core features of Alzheimer’s. Dr. Collier explains why none of these are first-line.

0.25 CME Credits. In this episode, we explore nine groundbreaking stories in mental health and psychiatric medicine, covering everything from healthcare fraud to the latest advancements in drug trials. First, we dive into the recent charges brought by the US Department of Justice against executives at Done, a California-based telehealth company, for alleged healthcare fraud. Done is accused of prescribing over 40 million Adderall pills to patients without proper evaluation, raising concerns about the balance between increasing mental healthcare access and responsible prescribing practices.